KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Intangibles: 2020-2025

Historic Intangibles for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $39.3 million.

  • AbCellera Biologics' Intangibles fell 25.21% to $39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.3 million, marking a year-over-year decrease of 25.21%. This contributed to the annual value of $42.1 million for FY2024, which is 65.03% down from last year.
  • Per AbCellera Biologics' latest filing, its Intangibles stood at $39.3 million for Q3 2025, which was down 2.34% from $40.3 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Intangibles high stood at $163.0 million for Q3 2022, and its period low was $39.3 million during Q3 2025.
  • In the last 3 years, AbCellera Biologics' Intangibles had a median value of $85.7 million in 2024 and averaged $83.6 million.
  • Its Intangibles has fluctuated over the past 5 years, first soared by 36.80% in 2021, then crashed by 65.31% in 2025.
  • Over the past 5 years, AbCellera Biologics' Intangibles (Quarterly) stood at $161.0 million in 2021, then dropped by 18.31% to $131.5 million in 2022, then dropped by 8.42% to $120.4 million in 2023, then plummeted by 65.03% to $42.1 million in 2024, then fell by 25.21% to $39.3 million in 2025.
  • Its last three reported values are $39.3 million in Q3 2025, $40.3 million for Q2 2025, and $41.2 million during Q1 2025.